vTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19 and the Alliance Global Partners Healthcare Company Showcase on May 20. The company's lead asset, cadisegliatin, is a potential first-in-class oral adjunctive therapy for type 1 diabetes currently in a U.S. Phase 3 trial with Breakthrough Therapy designation.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.